Skip to main content
ARWR logo

ARWR

Arrowhead Pharmaceuticals, Inc.
$71.91 -2.20 (-2.97%) At close · Jul 14
Market Cap
$10.13B
Shares
140,857,021

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue
$829.45M +23258.2%
FY2025 Revenue FY2011–FY2025
Net Income
-$1.63M +99.7%
FY2025 Net Income FY2006–FY2025
Operating Margin
11.86% +16938.9pp
FY2025 Operating Margin FY2011–FY2025
Diluted EPS
-$0.01 +99.8%
FY2025 Diluted EPS FY2010–FY2025
Operating Cash Flow
$179.55M +138.8%
FY2025 Operating Cash Flow FY2010–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010 FY2009 FY2008 FY2007 FY2006 FY2005 FY2004 FY2003
$622.01M $829.45M $3.55M $240.74M $243.23M $138.29M $87.99M $168.8M $16.14M $31.41M $158.33K $382K $175K $290.27K $146.88K $296.14K
$645.49K -$97.91K $35.97K $86.53K -$22.78K
$687.51M $607.16M $505.87M $353.19M $297.31M $206.34M $128.88M $81.05M $52.97M $50.9M $62.12M $47.27M $23.14M $8.71M $5.39M $3.28M $529.6K
$143.05M $123.94M $98.76M $92.55M $124.43M $80.98M $52.28M $26.56M $19.11M $17.5M $23.59M $7.93M $5.89M $3.49M $6.44M $3.8M $2.49M
$1.7M $1.7M $1.7M $1.7M $1.7M $1.7M $1.7M $1.7M $1.7M $1.7M $1.71M $1.05M $54.65K $236.01K $293.96K $241.81K $241.81K
$23.7M $22.2M $16.9M $10.7M $8.7M $6.6M $4.2M $2.7M $3M $2.99M $3.26M $2.34M $1.35M $1.75M $1.75M $267.98K $277.65K
$843.9M $731.1M $604.63M $445.74M $421.74M $287.32M $181.15M $107.61M $72.08M $68.4M $81.9M $96.36M $53.45M $24.88M $21.24M $10.13M $5.83M
-$221.9M $98.35M -$601.08M -$205M -$178.51M -$149.04M -$93.16M $61.19M -$55.94M -$37M -$81.74M -$95.97M -$53.28M -$24.59M -$21.09M -$9.83M -$5.83M
11.86% -16927.06% -85.16% -73.39% -107.77% -105.87% 36.25% -346.52% -117.79% -51627.09% -25124.08% -30443.59% -8471.29% -14358.61% -3319.48%
-$198.2M $120.55M -$584.18M -$194.3M -$169.81M -$142.44M -$88.96M $63.89M -$52.94M -$34.01M -$78.48M -$93.64M -$51.93M -$22.84M -$19.34M -$9.56M -$5.56M
$92.43M $89.36M $32.35M $18.33M $0 $0
-$30.37M -$46.81M -$11.38M -$1.49M $5.8M $8.19M $8.61M $6.96M $1.49M $2.62M $22.12K $4.04M -$5.44M -$7.11M -$1.02M $1.05M $1.52M
-$78.87K -$641.14K -$240.15K -$163.18K -$219.54K
$0 -$4.43M $1.71M $20K
-$252.26M $51.53M -$612.46M -$206.49M -$172.71M -$140.85M -$84.55M $68.15M -$54.45M -$34.38M -$81.72M -$91.94M -$58.72M -$31.7M -$22.11M -$8.79M -$4.31M
$19.6M $21.42M -$2.77M $2.78M $3.79M $2000 $2000 $174K $2400 $2400 $2400 $2400 $5300
-$298.78M -$1.63M -$599.49M -$205.28M -$176.06M -$140.85M -$84.55M $67.98M -$54.45M -$34.38M -$81.72M -$91.94M -$58.63M -$31.14M -$21.13M -$3.13M -$5.77M -$19.31M -$27.24M -$30.71M -$19.96M -$6.73M -$751.26K -$95.24K
-0.2% -16882.37% -85.27% -72.39% -101.85% -96.09% 40.27% -337.32% -109.46% -51614.64% -24068.29% -33502.97% -10729.22% -14383.61% -1056.56%
$29.05M $31.75M -$10.2M -$4M -$431K $0 $0 -$95.22K -$560.14K -$984.8K -$363.51K -$1.18M
-$140.94M -$84.14M $67.61M -$54.51M -$34.35M -$81.58M -$92.08M -$58.63M -$31.14M
USD/shares -$0.01 -$5.00 -$1.92 -$1.67 -$1.36 -$0.84 $0.72 -$0.65 -$0.47 -$1.90 -$0.44 -$0.90
USD/shares -$0.01 -$5.00 -$1.92 -$1.67 -$1.36 -$0.84 $0.69 -$0.65 -$0.47 -$0.40 -$0.90
shares 133.76M 119.78M 106.75M 105.43M 103.75M 100.72M 93.86M 83.64M 73.9M 61.05M 57.36M 46.93M 24M 11.13M 7.18M 6.43M
shares 133.76M 119.78M 106.75M 105.43M 103.75M 100.72M 98.61M 83.64M 73.9M 61.05M 57.36M 46.93M 24M 11.13M 7.83M 6.43M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
Biotechnology median 8.34×
EV/EBIT
Biotechnology median 25.45×
P/E (TTM)
Biotechnology median 7.56×

Valuation over time computed as of each quarter's filing date

Key facts CIK 879407 CUSIP 04280A100 13F (30d) 32 filings 27 filers Visit website Investor relations